High-Flow Nasal Oxygen for Preoxygenation
CA-1 · I.A.2.b.1 II.D.2.c.1 II.B.2.d
23Sources
6Kept
0Dropped
6 points
In obese patients high-flow nasal cannula lengthened safe apnoea time and was more comfortable, but did not reduce the odds of desaturating below 92% — it buys time rather than removing the risk.
PMID 36469483
kept
High-flow nasal oxygen achieved a higher PaO2 and about 131 seconds more safe apnoea time than facemask, without reducing desaturation during intubation.
PMID 35451383
kept
HFNO prolongs safe apnoea time and decreases desaturation incidence compared to conventional oxygen therapy, especially in high-risk patients like obese or cardiothoracic surgical patients.
PMID 41903885
kept
Median apnoea time in morbidly obese patients reached 18 minutes with either high-flow nasal or low-flow facemask oxygen, but desaturation below 92% was less likely with high flow (hazard ratio 0.27).
PMID 35027169
kept
High-flow nasal oxygen does not clear carbon dioxide: arterial CO2 accumulates across a wide range of flow rates, so treat it as apnoeic oxygenation and monitor CO2 rather than assuming ventilation.
PMID 41402219
kept
Compared with non-invasive ventilation, preoxygenating obese patients with high-flow nasal cannula gave a lower end-tidal oxygen and more desaturation below 95% (30% versus 12%), although patients found it far more comfortable.
PMID 31528849
kept
Decks
Oral boards prompts for you
No module in the boards bank matches this topic yet.